Novogen Limited (NVGN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.980.00 (0.00%)
At close: 4:00 PM EDT
People also watch:
NYMXPRANPBMDBIOCGENE
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open2.00
Prev Close1.98
Bid1.98 x 100
Ask1.99 x 1900
Day's Range1.95 - 2.01
52wk Range1.72 - 3.09
1y Target EstN/A
Market Cap33.43M
P/E Ratio (ttm)-3.77
Beta0.96
Volume19,018
Avg Vol (3m)46,571
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire14 days ago

    Conversion of Convertible Notes

    SYDNEY, Sept. 14 , 2016 /PRNewswire/ -- On 19 April 2013, the shareholders of  Novogen Limited  approved the issue of 60,000,000 convertible securities, with a face value of $1.5M, to the former securities ...

  • PR Newswire15 days ago

    Conversion of Convertible Notes

    SYDNEY, Sept. 14, 2016 /PRNewswire/ -- On 19 April 2013, the shareholders of Novogen Limited approved the issue of 60,000,000 convertible securities, with a face value of $1.5M, to the former securities ...

  • PR Newswire16 days ago

    US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer

    NASDAQ: NVGN) today announced that it had received confirmation from the United States Food and Drug Administration (FDA) that the Investigational New Drug (IND) application for Cantrixil (TRX-E-002-1) had been successfully opened, and the phase I study of Cantrixil in patients with ovarian cancer may therefore proceed as planned. Dr James Garner, CEO of Novogen, commented, "We are grateful to the FDA for their thorough and comprehensive review of our submission, and we are pleased to have their approval to move forward with the study.